Cerebellar Microbleed Distribution Patterns and Cerebral Amyloid Angiopathy.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 5 6 2019
medline: 19 2 2020
entrez: 5 6 2019
Statut: ppublish

Résumé

Background and Purpose- Hematoma location within the cerebellum may help identify the dominant small vessel disease type (cerebral amyloid angiopathy [CAA] versus nonamyloid small vessel disease). However, it is unknown whether this holds true for cerebral microbleeds (CMBs) within the cerebellum. We tested the hypothesis that cerebellar CMBs restricted to the cortex and vermis (defined as superficial regions) are associated with clinically diagnosed and pathology-verified CAA. Methods- Three hundred and seven consecutive spontaneous intracerebral hemorrhage (ICH) patients with a baseline magnetic resonance imaging that included susceptibility-weighted imaging or angiography were enrolled. Using a topographical template, cerebellar CMB patterns were defined as strictly superficial versus deep (cerebellar gray nuclei and white matter) or mixed (both regions involved). Thirty-six ICH patients with cerebellar CMBs and neuropathology data available were evaluated for the presence of CAA. Results- One hundred and thirty-five (44%) ICH patients had CMBs in the cerebellum. In the patient group with cerebellar CMBs, 85 (63%) showed a superficial pattern, and 50 (37%) had a deep/mixed pattern. Strictly superficial cerebellar CMBs were independently associated with a supratentorial pattern of probable CAA-ICH according to the Boston criteria (odds ratio, 1.6; CI, 1.03-2.5) and deep/mixed cerebellar CMBs with a pattern of deep/mixed ICH (odds ratio, 1.8; CI, 1.2-2.7). Pathologically verified CAA was present in 23 of 24 (96%) patients with superficial cerebellar CMBs versus 3 of 12 (25%) patients with deep/mixed cerebellar CMBs ( P<0.001). Conclusions- In ICH patients, cerebellar CMBs are relatively common and often restricted to superficial regions. A strictly superficial distribution of cerebellar CMBs is associated with clinically diagnosed and pathologically verified CAA.

Identifiants

pubmed: 31159702
doi: 10.1161/STROKEAHA.119.024843
pmc: PMC6599711
mid: NIHMS1528919
doi:

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1727-1733

Subventions

Organisme : NIA NIH HHS
ID : R01 AG026484
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS083711
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005134
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG047975
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS070834
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS036695
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Neurology. 2017 Jun 6;88(23):2162-2168
pubmed: 28476760
Lancet Neurol. 2009 Feb;8(2):165-74
pubmed: 19161908
J Neurol. 1987 Aug;234(6):371-6
pubmed: 3655840
Neurology. 2006 Jan 10;66(1):23-9
pubmed: 16401840
AJNR Am J Neuroradiol. 1999 Apr;20(4):637-42
pubmed: 10319975
Brain Res Bull. 1983 Oct;11(4):419-80
pubmed: 6652521
Stroke. 1997 Jul;28(7):1418-22
pubmed: 9227694
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Stroke. 2018 Jan;49(1):207-210
pubmed: 29183952
Stroke. 2013 Oct;44(10):2782-6
pubmed: 23920014
Alzheimers Dement. 2015 Dec;11(12):1480-1488
pubmed: 26079413
Ann Neurol. 1991 Nov;30(5):637-49
pubmed: 1763890
Surg Neurol. 1996 Sep;46(3):235-9
pubmed: 8781592
Neurology. 2017 Nov 21;89(21):2128-2135
pubmed: 29070669
Arch Neurol. 1964 Feb;10:200-17
pubmed: 14088254
Stroke. 2018 Feb;49(2):491-497
pubmed: 29335334
Stroke. 1993 Jan;24(1):49-51
pubmed: 8418549
Neurology. 2018 Jan 9;90(2):e119-e126
pubmed: 29247070
J Neurol Sci. 1993 Jun;116(2):135-41
pubmed: 8336159
Neurology. 2017 Mar 21;88(12):1157-1164
pubmed: 28228568
Neurology. 2010 Apr 27;74(17):1346-50
pubmed: 20421578
J Nerv Ment Dis. 1965 Jan;140:38-57
pubmed: 14260181
Neurology. 2001 Feb 27;56(4):537-9
pubmed: 11222803
Stroke. 1983 Nov-Dec;14(6):915-23
pubmed: 6658995
Brain. 2015 Aug;138(Pt 8):2126-39
pubmed: 26115675

Auteurs

Marco Pasi (M)

Hemorrhagic Stroke Research Program, Department of Neurology, J. Philip Kistler Stroke Research Center (M.P., T.P., A.C., S.D.S., L.X., A.D.W., A.V., M.E.G., S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston.

Thanakit Pongpitakmetha (T)

From the Department of Pharmacology, Chulalongkorn University, Bangkok, Thailand (T.P.).
Hemorrhagic Stroke Research Program, Department of Neurology, J. Philip Kistler Stroke Research Center (M.P., T.P., A.C., S.D.S., L.X., A.D.W., A.V., M.E.G., S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston.

Andreas Charidimou (A)

Hemorrhagic Stroke Research Program, Department of Neurology, J. Philip Kistler Stroke Research Center (M.P., T.P., A.C., S.D.S., L.X., A.D.W., A.V., M.E.G., S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston.

Sanjula D Singh (SD)

Hemorrhagic Stroke Research Program, Department of Neurology, J. Philip Kistler Stroke Research Center (M.P., T.P., A.C., S.D.S., L.X., A.D.W., A.V., M.E.G., S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston.

Hsin-Hsi Tsai (HH)

Department of Neurology, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan (H.-H.T.).

Li Xiong (L)

Hemorrhagic Stroke Research Program, Department of Neurology, J. Philip Kistler Stroke Research Center (M.P., T.P., A.C., S.D.S., L.X., A.D.W., A.V., M.E.G., S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston.

Gregoire Boulouis (G)

Department of Neuroradiology, INSERM UMR 894, Centre Hospitalier Sainte-Anne, Université Paris-Descartes, France (G.B.).

Andrew D Warren (AD)

Hemorrhagic Stroke Research Program, Department of Neurology, J. Philip Kistler Stroke Research Center (M.P., T.P., A.C., S.D.S., L.X., A.D.W., A.V., M.E.G., S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston.

Jonathan Rosand (J)

Division of Neurocritical Care and Emergency Neurology (J.R.), Massachusetts General Hospital, Harvard Medical School, Boston.

Matthew P Frosch (MP)

C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston (M.P.F.).

Anand Viswanathan (A)

Hemorrhagic Stroke Research Program, Department of Neurology, J. Philip Kistler Stroke Research Center (M.P., T.P., A.C., S.D.S., L.X., A.D.W., A.V., M.E.G., S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston.

M Edip Gurol (ME)

Hemorrhagic Stroke Research Program, Department of Neurology, J. Philip Kistler Stroke Research Center (M.P., T.P., A.C., S.D.S., L.X., A.D.W., A.V., M.E.G., S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston.

Steven M Greenberg (SM)

Hemorrhagic Stroke Research Program, Department of Neurology, J. Philip Kistler Stroke Research Center (M.P., T.P., A.C., S.D.S., L.X., A.D.W., A.V., M.E.G., S.M.G.), Massachusetts General Hospital, Harvard Medical School, Boston.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH